# NGGT

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nggt

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Total disclosed funding: $70M
- Latest round: Series B (Jul 11, 2023)
- Investors on record: 9

## About

Established in 2020 and based in Suzhou, China, NGGT is a biopharmaceutical company that develops genetic drugs and provides corresponding therapeutic services. The company has built a 1000L scale cGMP manufacturing system, and several differentiated R&D pipelines have completed clinical IIT studies or are in the process of registered clinical studies. Dr. Lixin Jiang, the founder of the company, has 25 years of experience in gene therapy and related biopharmaceuticals, and has presided over the national "Gene Vector Platform Technology Development and Industrialization" project. In July 2023, the company closed a round of USD 40 million series B funding.

The company focuses on the key technology research of gene drug therapy for viral infections, the development of anti-HIV gene drugs, and the research and development of gene drugs against Hepatitis B virus infection, mainly covering genetic diseases such as blood system, ophthalmology system, and neurological diseases. Its current products include NGGT001, a gene therapy drug targeting retinitis pigmentosa, which received IND approval from the FDA in April 2023, and NGGT002, a gene therapy drug targeting metabolic diseases that is administered through a systemic delivery system, which received Orphan Drug Designation from the FDA in January 2023.

## Funding rounds

- Series B, Jul 11, 2023, $40M — Detong Capital, NLVC, Weidu Capital, Zhongxin Capital, Shanghai Healthcare Capital, Leader Venture Capital, Guangda Huitong Engineering Technology Research Institute Capital
- Series A, Apr 15, 2021, $30M — NLVC, YuanBio Venture, Kington Capital, Weidu Capital

## Investors

- NLVC (https://capitalatlas.ai/funds/nlvc) — Series A, Series B
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Kington Capital (https://capitalatlas.ai/funds/kington-capital) — Series A
- Weidu Capital (https://capitalatlas.ai/funds/weidu-capital) — Series A, Series B
- Detong Capital (https://capitalatlas.ai/funds/detong-capital) — Series B
- Zhongxin Capital — Series B
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series B
- Leader Venture Capital (https://capitalatlas.ai/funds/leader-venture-capital) — Series B
- Guangda Huitong Engineering Technology Research Institute Capital (https://capitalatlas.ai/funds/guangda-huitong-engineering-technology-research-institute-ca) — Series B